- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00747695
A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive
January 7, 2011 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With GERD 1 to 11 Years Old, Inclusive
The purpose of the study is to evaluate the pharmacokinetics, pharmacodynamics and safety of rabeprazole after single and multiple daily administration in children between the ages of 1 and 11 years, inclusive, with GERD.
Study Overview
Detailed Description
This is an open-label (both the physician and the patient know the name of the study medication), multi-center, Phase 1 study, consisting of 2 parts.
The first part of the study will be non-randomized, all patients will receive the same dose.
In the second part of the study, patients will be randomized (study medication assigned by chance) into 2 dose groups.
The purpose of the study is to evaluate the pharmacokinetics, pharmacodynamics (clinical global impressions and formulation palatability) and safety of rabrepazole after single and multiple daily administration at 2 dose levels in children between the ages of 1 and 11 years, inclusive, with GERD.
As this study is an exploratory assessment of the pharmacokinetics, pharmacodynamics and safety of rabeprazole in children, no formal hypothesis testing is applied.
Safety and tolerability, including monitoring of adverse events, clinical laboratory results, physical examination, vital signs and ECG measurements, will be evaluated throughout the study.
Patients will receive rabeprazole sodium as single daily oral doses for 5 successive days as a bead formulation.
Patients in the first part of the study will receive single and multiple daily every 24 hours doses of 0.14 mg/kg, using increments of 1 mg dose.
Safety and pk data from part 1 of the study will determine the 2 dosages to be studied in part 2 of the study.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 11 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Boy and girls and a minimum weight of 10 kg with endoscopically proven GERD including an endoscopic examination as part of their diagnostic evaluation
- Patients who have been treated with, or are currently receiving a proton pump inhibitor (PPI), H2 blockers, or antacids are eligible (as long as they can go off antacids for 24 hours, and PPIs and H2 blockers for 3 days prior to dosing, except for cimetidine, which must be discontinued for at least 7 days prior to dosing) and remain off these medications for the treatment period
- Patients who are generally healthy, other than the presence of GERD, with the exception of the following: Patients with stable asthma/reactive airway disease or cystic fibrosis-dependent GERD symptoms on stable treatment regimens or subjects on stable doses of allergy and attention deficit disorder medicines.
Exclusion Criteria:
- Patients who have a history of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders, lipid abnormalities, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results
- Primary pulmonary or ENT symptoms
- Presence of "warning signals", suggesting cause of vomiting/regurgitation other than GERD
- History of primary esophageal motility disorders or systemic condition affecting the esophagus
- History of eosinophilic esophagitis, persistent milk protein allergy, or allergic gastroenteropathy
- History of or current presence of peptic ulcers
- Current presence of Helicobacter pylori
- History of definitive acid-lowering surgery
- Significant arrhythmias.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Pharmacokinetic, pharmacodynamic and safety parameters of rabeprazole will be listed and summarized.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
September 4, 2008
First Submitted That Met QC Criteria
September 4, 2008
First Posted (Estimate)
September 5, 2008
Study Record Updates
Last Update Posted (Estimate)
January 10, 2011
Last Update Submitted That Met QC Criteria
January 7, 2011
Last Verified
January 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR013945
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GERD
-
Baylor Research InstituteNot yet recruiting
-
Ohio State UniversityCompleted
-
EndoStim Inc.TerminatedGERDDenmark, Netherlands, Germany, Austria, United Kingdom, Argentina, Mexico
-
Chong Kun Dang PharmaceuticalCompleted
-
Chong Kun Dang PharmaceuticalRecruiting
-
Cinclus Pharma Holding ABActive, not recruiting
-
Korea United Pharm. Inc.Completed
-
Korea United Pharm. Inc.CompletedGERDKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknown
Clinical Trials on Rabeprazole sodium
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Eisai Co., Ltd.Completed
-
Eisai Inc.CompletedSymptomatic Gastroesophageal Reflux Disease (sGERD)United States
-
Janssen Research & Development, LLCEisai Inc.CompletedGastroesophageal Reflux Disease (GERD)United States, Poland, United Kingdom, Belgium, Brazil
-
Yungjin Pharm. Co., Ltd.Seoul National University HospitalCompletedGastroesophageal Reflux DiseaseKorea, Republic of
-
Johnson & Johnson Pharmaceutical Research & Development...Eisai Inc.CompletedGastroesophageal RefluxUnited States, Belgium, Israel, Poland, Australia, Netherlands, South Africa, Hungary, Bulgaria, Denmark
-
Zeria PharmaceuticalCompleted
-
Zeria PharmaceuticalCompleted
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed